Sanofi Multiple Myeloma Drug Approved in Canada
08 Julho 2020 - 9:05AM
Dow Jones News
By Matt Grossman
Sanofi's Sarclisa, an immunotherapy for patients with multiple
myeloma, has been approved by Canada's health authority, Sanofi
said Wednesday.
The treatment was approved to treat patients who have had at
least two prior therapies including lenalidomide and a proteasome
inhibitor. Sarclisa was approved to be used in conjunction with
pomalidomide and dexamethasone.
The drug's approval was based on a study that showed
statistically significant improvement in patients' progression-free
survival, Sanofi said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
July 08, 2020 07:50 ET (11:50 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
